Cambridge University Press
  • Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • The
    Prescriber's Guide
  • Essential
    Psychopharmacology
  • Essential
    Neuropharmacology
  • Other
    Resources
    • Next Generation Antidepressants:
      Beyer and Stahl
  • Stahl's
    Illustrated
  • Drug
    Interaction
 
  • My Bookmarks
  • TOC
  • Mitoxantrone
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

Mitoxantrone

Therapeutics

Brands

• Novantrone

Generic?

Yes

Class

• Antineoplastic agent, immunomodulator

Commonly Prescribed for

(FDA approved in bold)
• Reducing neurologic disability or relapses in patients with secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (MS)
• Acute nonlymphoblastic leukemia
• Prostate cancer
• Breast cancer
• Non-Hodgkin's lymphoma

How the Drug Works

• A DNA-reactive agent that causes crosslinks and strand breaks, interferes with DNA uncoiling and repair, and has a cytocidal effect on cells. In MS, it appears to blunt the immune processes believed to be responsible in part for the disease
• It suppresses B-cell, T-cell, and macrophage function, impairs antigen proliferation, and decreases the secretion of inflammatory cytokines, including TNFα, IL-2, and interferon gamma, that mediate demyelination
• Due to its slow release from sequestered tissue into blood it is a long-acting immunosuppressant

How Long Until It Works

• MS: Months-years. In trials treated patients had fewer relapses at 1 and 2 years

If It Works

• MS: Continue to use for up to 2-3 years or a total of 140 mg/m2 then discontinue because of cardiotoxicity risk

If It Doesn't Work

• For patients failing first-line agents in MS (interferons, glatiramer) and mitoxantrone with frequent relapses (measured by clinical outcome and MRI accumulation of lesions) consider using natalizumab, monthly methylprednisolone, or pulse cyclophosphamide

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Acute attacks in MS are often treated with glucocorticoids, especially if there is functional impairment due to vision loss, weakness, or cerebellar symptoms
• Treat common clinical symptoms with appropriate medication for spasticity (baclofen, tizanidine), neuropathic pain, and fatigue (modafinil)
• Generally not combined with most other MS disease-modifying treatments (natalizumab, interferons, glatiramer) but 1 study showed that adding monthly mitoxantrone to monthly doses of 1 gram methylprednisolone improved outcomes

Tests

• Assess cardiac left ventricular function using echocardiogram or MUGA (multi gated acquisition scan) at baseline and before each dose of mitoxantrone. Obtain a baseline blood count and recheck if symptoms of infection occur
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$261
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us